Home
- Naturade Significantly Strengthens Balance Sheet; Receives $2.5 Million in Capital from Westgate Equity Partners, L.P.
- Natrol Appoints Vincent Andrich VP Sales for Prolab Division
- Vermont Pure Holdings, Ltd. Announces Record Fiscal Year 2001 Results
- Body Shop Reports 24.8 Mil Euro Sales Revenues
- Spectrum Organic Products Responds to FDA Letter Regarding Use of Non-GMO Seal on Canola Oil Label
- Supplement Group Targets Consumer Education
- Advanced Nutraceuticals, Inc. Announces 2001 Year End Results And Additional Financing
- ADM Awarded Nutraceuticals Patent Patent Creates Proprietary Position for ADM in Fast-Growing Nutraceutical Market
- Tantivy Sciences Obtains Exclusive License to Unique Nutraceutical Products
- Top GNC Executives Tour Pittsburgh Market to Present New Business Plan and Expansion Possibilities; Meeting will focus on new business strategies and growth
- Nutrition 21 Receives Patent For the Nutritional Treatment of Type 2 Diabetes; Patent Presents New Pharmaceutical Licensing Opportunities
- ConsumerLab.com Finds Most B-vitamin Supplements Contain What They Claim, But Often Exceed Safe Levels - Consumers Cautioned to Be Aware of Side Effects with High Dose Products
- Nutraceutix, Inc., Nutravite Announcement Commercial Availability of CDT™ Glucosamine for Canadian Marketplace
- Harvey Kamil Appointed President of NBTY, Inc. - Scott Rudolph to Continue as Chairman and CEO
- drugstore.com Expects to Reach Profitability Target in 2003
- Human Genome Project Leads to Innovative Healthcare
- NPIcenter’s Career Center targets nutraceutical Industry
- Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders
- Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders
- Editorial: An Exercise in Synergy
- NBTY, Inc. Appoints Harvey Kamil President, Scott Rudolph To Continue As Chairman And CEO
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- LignisulMSM vs Naproxen for Osteoarthritis Clinical Trial Gets Underway
- Natural Health Trends Corp. Launches Lexxus Taiwan
- FDA Presents Compliance Guide for Structure/Function Claims
- New TrimFit® Bars Redefine Energy Bar Category
- New TrimFit® Bars Redefine Energy Bar Category
- Probiata® Offers Safe, Natural and Effective Alternative
- Alive & Well with Michelle Harris
- Be Well and Get Rewarded! Find Personalized Wellness Solutions and Earn Free Vitamins at NatureMade.com
- Consumers Search for Healthy Cleaning Products That Work
- Nordic Naturals: Omega 3 Fatty Acids
- Cyanotech Names Bob Capelli as Director of Sales
- Triarco Clinical Trial Indicates Aminogen® Boosts Branched-Chain Amino Acids Over 250%
- Triarco Clinical Trial Indicates Aminogen® Boosts Branched-Chain Amino Acids Over 250%
- Triarco Clinical Trial Indicates Aminogen® Boosts Branched-Chain Amino Acids Over 250%
- Triarco Clinical Trial Indicates Aminogen® Increases Nitrogen Retention By 32%!
Triarco clinical trial studied Aminogen’s impact on nitrogen balance, in subjects taking the patented enzyme formula with their whey protein. Nitrogen excretion and retention levels were measured every 4 hours over a 24-hour period.
- Triarco Clinical Trial Indicates Aminogen® Increases Nitrogen Retention By 32%!
Triarco clinical trial studied Aminogen’s impact on nitrogen balance, in subjects taking the patented enzyme formula with their whey protein. Nitrogen excretion and retention levels were measured every 4 hours over a 24-hour period.
- Triarco Clinical Trial Indicates Aminogen® Increases Nitrogen Retention By 32%!
Triarco clinical trial studied Aminogen’s impact on nitrogen balance, in subjects taking the patented enzyme formula with their whey protein. Nitrogen excretion and retention levels were measured every 4 hours over a 24-hour period.
- Triarco Clinical Trial Indicates Aminogen® Increases Nitrogen Retention By 32%!
Triarco clinical trial studied Aminogen’s impact on nitrogen balance, in subjects taking the patented enzyme formula with their whey protein. Nitrogen excretion and retention levels were measured every 4 hours over a 24-hour period.
- New Study: Pine Bark Extract Reduces ADHD Symptoms In Children
New randomized, double-blind placebo-controlled study to be published in the June 17 edition of the journal of European Child & Adolescent Psychiatry shows a significant reduction of Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms in children after supplementing with Pycnogenol® (1 mg of Pycnogenol or placebo for every kilogram of body weight) for one month.
- New Study: Pine Bark Extract Reduces ADHD Symptoms In Children
New randomized, double-blind placebo-controlled study to be published in the June 17 edition of the journal of European Child & Adolescent Psychiatry shows a significant reduction of Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms in children after supplementing with Pycnogenol® (1 mg of Pycnogenol or placebo for every kilogram of body weight) for one month.
- New Study: Pine Bark Extract Reduces ADHD Symptoms In Children
New randomized, double-blind placebo-controlled study to be published in the June 17 edition of the journal of European Child & Adolescent Psychiatry shows a significant reduction of Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms in children after supplementing with Pycnogenol® (1 mg of Pycnogenol or placebo for every kilogram of body weight) for one month.
- New Study: Pine Bark Extract Reduces ADHD Symptoms In Children
New randomized, double-blind placebo-controlled study to be published in the June 17 edition of the journal of European Child & Adolescent Psychiatry shows a significant reduction of Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms in children after supplementing with Pycnogenol® (1 mg of Pycnogenol or placebo for every kilogram of body weight) for one month.
- New Studies Focus On Lignans and Breast Health
Study conducted in Germany and published this month in the European Journal of Cancer Prevention, reported that women who had a higher lignan intake decreased their risk of breast cancer by 58 percent. A study in progress in Australia is investigating the effects of a flax lignan extract, LinumLife® EXTRA on markers of breast health in postmenopausal women.
- New Studies Focus On Lignans and Breast Health
Study conducted in Germany and published this month in the European Journal of Cancer Prevention, reported that women who had a higher lignan intake decreased their risk of breast cancer by 58 percent. A study in progress in Australia is investigating the effects of a flax lignan extract, LinumLife® EXTRA on markers of breast health in postmenopausal women.
- New Studies Focus On Lignans and Breast Health
Study conducted in Germany and published this month in the European Journal of Cancer Prevention, reported that women who had a higher lignan intake decreased their risk of breast cancer by 58 percent. A study in progress in Australia is investigating the effects of a flax lignan extract, LinumLife® EXTRA on markers of breast health in postmenopausal women.
- New Studies Focus On Lignans and Breast Health
Study conducted in Germany and published this month in the European Journal of Cancer Prevention, reported that women who had a higher lignan intake decreased their risk of breast cancer by 58 percent. A study in progress in Australia is investigating the effects of a flax lignan extract, LinumLife® EXTRA on markers of breast health in postmenopausal women.
- Meta-Analysis Confirms Venaforce Horse Chestnut Extract To Be Effective for CVI
Study appeared in the journal, Advances in Therapy, Jan/Feb, 2006 - shown in meta-analysis of five studies to be effective in reducing the symptoms associated with chronic venous insufficiency, such as lower leg swelling.
- Meta-Analysis Confirms Venaforce Horse Chestnut Extract To Be Effective for CVI
Study appeared in the journal, Advances in Therapy, Jan/Feb, 2006 - shown in meta-analysis of five studies to be effective in reducing the symptoms associated with chronic venous insufficiency, such as lower leg swelling.
- Plants Help Fight Cardiovascular Disorders
On the occasion of the XIV International Symposium on Atherosclerosis in Rome, Paolo Morazzoni, President of the Scientific Board of Indena, is to give a Master Lecture on how standardised extracts of edible plants can be used to optimise nutrition.
- Plants Help Fight Cardiovascular Disorders
On the occasion of the XIV International Symposium on Atherosclerosis in Rome, Paolo Morazzoni, President of the Scientific Board of Indena, is to give a Master Lecture on how standardised extracts of edible plants can be used to optimise nutrition.
- Plants Help Fight Cardiovascular Disorders
On the occasion of the XIV International Symposium on Atherosclerosis in Rome, Paolo Morazzoni, President of the Scientific Board of Indena, is to give a Master Lecture on how standardised extracts of edible plants can be used to optimise nutrition.
- Plants Help Fight Cardiovascular Disorders
On the occasion of the XIV International Symposium on Atherosclerosis in Rome, Paolo Morazzoni, President of the Scientific Board of Indena, is to give a Master Lecture on how standardised extracts of edible plants can be used to optimise nutrition.
- Plants Help Fight Cardiovascular Disorders
On the occasion of the XIV International Symposium on Atherosclerosis in Rome, Paolo Morazzoni, President of the Scientific Board of Indena, is to give a Master Lecture on how standardised extracts of edible plants can be used to optimise nutrition.
- Web Site Detailing Zeaxanthin Science Adds New Pola Group Study
Company presents comprehensive, easily accessible abstract collection is readily available on the web site www.Chrysantis.com. The most recent addition is the study conducted by the Ocular Pathologies Associated with Age group.
- Web Site Detailing Zeaxanthin Science Adds New Pola Group Study
Company presents comprehensive, easily accessible abstract collection is readily available on the web site www.Chrysantis.com. The most recent addition is the study conducted by the Ocular Pathologies Associated with Age group.
- Web Site Detailing Zeaxanthin Science Adds New Pola Group Study
Company presents comprehensive, easily accessible abstract collection is readily available on the web site www.Chrysantis.com. The most recent addition is the study conducted by the Ocular Pathologies Associated with Age group.
- Web Site Detailing Zeaxanthin Science Adds New Pola Group Study
Company presents comprehensive, easily accessible abstract collection is readily available on the web site www.Chrysantis.com. The most recent addition is the study conducted by the Ocular Pathologies Associated with Age group.
- Web Site Detailing Zeaxanthin Science Adds New Pola Group Study
Company presents comprehensive, easily accessible abstract collection is readily available on the web site www.Chrysantis.com. The most recent addition is the study conducted by the Ocular Pathologies Associated with Age group.
- New Study Shows Cinnamon Extract Lowers Blood Sugar Levels in People with Type 2 Diabetes
Placebo-controlled, double-blind study from the University of Hannover in Hannover, Germany published in a recent issue of the European Journal of Clinical Investigation, evaluated the effect of a water-soluble cinnamon extract on glycemic control and the lipid profile of Western patients with type 2 diabetes.
- New Study Shows Cinnamon Extract Lowers Blood Sugar Levels in People with Type 2 Diabetes
Placebo-controlled, double-blind study from the University of Hannover in Hannover, Germany published in a recent issue of the European Journal of Clinical Investigation, evaluated the effect of a water-soluble cinnamon extract on glycemic control and the lipid profile of Western patients with type 2 diabetes.
- New Study Shows Cinnamon Extract Lowers Blood Sugar Levels in People with Type 2 Diabetes
Placebo-controlled, double-blind study from the University of Hannover in Hannover, Germany published in a recent issue of the European Journal of Clinical Investigation, evaluated the effect of a water-soluble cinnamon extract on glycemic control and the lipid profile of Western patients with type 2 diabetes.
- Study: Soy Germ Isoflavones Reduce Bone Loss
A new study published in this month's European Journal of Nutrition demonstrates a strong correlation between reducing bone loss in non-obese postmenopausal women and the dose-dependent effect of soy germ isoflavones.
- Study: Soy Germ Isoflavones Reduce Bone Loss
A new study published in this month's European Journal of Nutrition demonstrates a strong correlation between reducing bone loss in non-obese postmenopausal women and the dose-dependent effect of soy germ isoflavones.
- Study: Soy Germ Isoflavones Reduce Bone Loss
A new study published in this month's European Journal of Nutrition demonstrates a strong correlation between reducing bone loss in non-obese postmenopausal women and the dose-dependent effect of soy germ isoflavones.
- Study: Soy Germ Isoflavones Reduce Bone Loss
A new study published in this month's European Journal of Nutrition demonstrates a strong correlation between reducing bone loss in non-obese postmenopausal women and the dose-dependent effect of soy germ isoflavones.
- Study: Soy Germ Isoflavones Reduce Bone Loss
A new study published in this month's European Journal of Nutrition demonstrates a strong correlation between reducing bone loss in non-obese postmenopausal women and the dose-dependent effect of soy germ isoflavones.
- New Study Demonstrates That Bifantis(TM) (Bifidobacterium infantis 35624) Offers Relief for Women With Irritable Bowel Syndrome
study published in the July issue of the American Journal of Gastroenterology found that Bifantis (Bifidobacterium infantis 35624) may help relieve many of the symptoms associated with irritable bowel syndrome (IBS) in women, including diarrhea and constipation.
- New Study Demonstrates That Bifantis(TM) (Bifidobacterium infantis 35624) Offers Relief for Women With Irritable Bowel Syndrome
study published in the July issue of the American Journal of Gastroenterology found that Bifantis (Bifidobacterium infantis 35624) may help relieve many of the symptoms associated with irritable bowel syndrome (IBS) in women, including diarrhea and constipation.
- New Study Demonstrates That Bifantis(TM) (Bifidobacterium infantis 35624) Offers Relief for Women With Irritable Bowel Syndrome
study published in the July issue of the American Journal of Gastroenterology found that Bifantis (Bifidobacterium infantis 35624) may help relieve many of the symptoms associated with irritable bowel syndrome (IBS) in women, including diarrhea and constipation.
- New Study Demonstrates That Bifantis(TM) (Bifidobacterium infantis 35624) Offers Relief for Women With Irritable Bowel Syndrome
study published in the July issue of the American Journal of Gastroenterology found that Bifantis (Bifidobacterium infantis 35624) may help relieve many of the symptoms associated with irritable bowel syndrome (IBS) in women, including diarrhea and constipation.
- New Study Demonstrates That Bifantis(TM) (Bifidobacterium infantis 35624) Offers Relief for Women With Irritable Bowel Syndrome
study published in the July issue of the American Journal of Gastroenterology found that Bifantis (Bifidobacterium infantis 35624) may help relieve many of the symptoms associated with irritable bowel syndrome (IBS) in women, including diarrhea and constipation.
- Study Shows Pine Bark Naturally Decreases Severe Chronic Venous Insufficiency
Recent findings published in the journal of Clinical and Applied Thrombosis/Hematosis show a significant symptom reduction of chronic venous insufficiency (CVI) in patients after supplementing with Pycnogenol, with Pycnogenol more effective in reducing edema (leg swelling), tight calves, skin alterations, pain during walking and swelling limbs than Daflon, a combination of diosmin and hesperidin and a commonly prescribed drug used to treat CVI.
- Study Shows Pine Bark Naturally Decreases Severe Chronic Venous Insufficiency
Recent findings published in the journal of Clinical and Applied Thrombosis/Hematosis show a significant symptom reduction of chronic venous insufficiency (CVI) in patients after supplementing with Pycnogenol, with Pycnogenol more effective in reducing edema (leg swelling), tight calves, skin alterations, pain during walking and swelling limbs than Daflon, a combination of diosmin and hesperidin and a commonly prescribed drug used to treat CVI.
- Study Shows Pine Bark Naturally Decreases Severe Chronic Venous Insufficiency
Recent findings published in the journal of Clinical and Applied Thrombosis/Hematosis show a significant symptom reduction of chronic venous insufficiency (CVI) in patients after supplementing with Pycnogenol, with Pycnogenol more effective in reducing edema (leg swelling), tight calves, skin alterations, pain during walking and swelling limbs than Daflon, a combination of diosmin and hesperidin and a commonly prescribed drug used to treat CVI.
- Study Shows Pine Bark Naturally Decreases Severe Chronic Venous Insufficiency
Recent findings published in the journal of Clinical and Applied Thrombosis/Hematosis show a significant symptom reduction of chronic venous insufficiency (CVI) in patients after supplementing with Pycnogenol, with Pycnogenol more effective in reducing edema (leg swelling), tight calves, skin alterations, pain during walking and swelling limbs than Daflon, a combination of diosmin and hesperidin and a commonly prescribed drug used to treat CVI.
- Preliminary Data from Human Clinical Trial Shows Vectomega®, Has Positive Results in Numerous Areas of Health
Preliminary findings from a recent human trial by French doctors demonstrate that 2 tablets per day of Vectomega® improve cardiovascular health by reducing cholesterol, triglycerides and increasing HDL-c in a healthy population, among other benefits.
- Preliminary Data from Human Clinical Trial Shows Vectomega®, Has Positive Results in Numerous Areas of Health
Preliminary findings from a recent human trial by French doctors demonstrate that 2 tablets per day of Vectomega® improve cardiovascular health by reducing cholesterol, triglycerides and increasing HDL-c in a healthy population, among other benefits.
- Preliminary Data from Human Clinical Trial Shows Vectomega®, Has Positive Results in Numerous Areas of Health
Preliminary findings from a recent human trial by French doctors demonstrate that 2 tablets per day of Vectomega® improve cardiovascular health by reducing cholesterol, triglycerides and increasing HDL-c in a healthy population, among other benefits.
- Indena and Nerviano Medical Sciences Agree To Scale Up New High Potency Molecules
Companies announce a co-development agreement, under which Indena has commissioned Nerviano to handle the scale up and manufacturing of two new drug candidates for preclinical and clinical development: IDN 5404 and IDN 5243.
- Indena and Nerviano Medical Sciences Agree To Scale Up New High Potency Molecules
Companies announce a co-development agreement, under which Indena has commissioned Nerviano to handle the scale up and manufacturing of two new drug candidates for preclinical and clinical development: IDN 5404 and IDN 5243.
- Indena and Nerviano Medical Sciences Agree To Scale Up New High Potency Molecules
Companies announce a co-development agreement, under which Indena has commissioned Nerviano to handle the scale up and manufacturing of two new drug candidates for preclinical and clinical development: IDN 5404 and IDN 5243.
- Indena and Nerviano Medical Sciences Agree To Scale Up New High Potency Molecules
Companies announce a co-development agreement, under which Indena has commissioned Nerviano to handle the scale up and manufacturing of two new drug candidates for preclinical and clinical development: IDN 5404 and IDN 5243.
- Indena and Nerviano Medical Sciences Agree To Scale Up New High Potency Molecules
Companies announce a co-development agreement, under which Indena has commissioned Nerviano to handle the scale up and manufacturing of two new drug candidates for preclinical and clinical development: IDN 5404 and IDN 5243.
- New Studies Indicate That Tocomin® / Tocomin® SupraBio(TM) Supplementation Elevates Blood Levels Sufficiently to Protect Against Stroke-Induced Neurodegeneration
Two NIH-funded studies conducted at the Ohio State University Medical Center, published in the May, 2006 issue of the journal Antioxidant & Redox Signaling and June 26th issue of the Journal of Neurochemistry, demonstrate that taking tocotrienols (Tocomin® and Tocomin® SupraBioTM) orally is an effective way to elevate blood plasma levels to concentrations that could help protect against neurological damage resulting from stroke
- New Studies Indicate That Tocomin® / Tocomin® SupraBio(TM) Supplementation Elevates Blood Levels Sufficiently to Protect Against Stroke-Induced Neurodegeneration
Two NIH-funded studies conducted at the Ohio State University Medical Center, published in the May, 2006 issue of the journal Antioxidant & Redox Signaling and June 26th issue of the Journal of Neurochemistry, demonstrate that taking tocotrienols (Tocomin® and Tocomin® SupraBioTM) orally is an effective way to elevate blood plasma levels to concentrations that could help protect against neurological damage resulting from stroke
- New Studies Indicate That Tocomin® / Tocomin® SupraBio(TM) Supplementation Elevates Blood Levels Sufficiently to Protect Against Stroke-Induced Neurodegeneration
Two NIH-funded studies conducted at the Ohio State University Medical Center, published in the May, 2006 issue of the journal Antioxidant & Redox Signaling and June 26th issue of the Journal of Neurochemistry, demonstrate that taking tocotrienols (Tocomin® and Tocomin® SupraBioTM) orally is an effective way to elevate blood plasma levels to concentrations that could help protect against neurological damage resulting from stroke
- Reduction of Inducible Arrhythmia in Patients with Cardiovascular Disease by Fish Oil
Dr. R. Metcalf presented highly original findings this morning on DHA/EPA Omega-3 fatty acids and cardiac arrhythmias from a recent pilot trial.
- Reduction of Inducible Arrhythmia in Patients with Cardiovascular Disease by Fish Oil
Dr. R. Metcalf presented highly original findings this morning on DHA/EPA Omega-3 fatty acids and cardiac arrhythmias from a recent pilot trial.
- Reduction of Inducible Arrhythmia in Patients with Cardiovascular Disease by Fish Oil
Dr. R. Metcalf presented highly original findings this morning on DHA/EPA Omega-3 fatty acids and cardiac arrhythmias from a recent pilot trial.
- Reduction of Inducible Arrhythmia in Patients with Cardiovascular Disease by Fish Oil
Dr. R. Metcalf presented highly original findings this morning on DHA/EPA Omega-3 fatty acids and cardiac arrhythmias from a recent pilot trial.
- Reduction of Inducible Arrhythmia in Patients with Cardiovascular Disease by Fish Oil
Dr. R. Metcalf presented highly original findings this morning on DHA/EPA Omega-3 fatty acids and cardiac arrhythmias from a recent pilot trial.
- Reduction of Inducible Arrhythmia in Patients with Cardiovascular Disease by Fish Oil
Dr. R. Metcalf presented highly original findings this morning on DHA/EPA Omega-3 fatty acids and cardiac arrhythmias from a recent pilot trial.
- Reduction of Inducible Arrhythmia in Patients with Cardiovascular Disease by Fish Oil
Dr. R. Metcalf presented highly original findings this morning on DHA/EPA Omega-3 fatty acids and cardiac arrhythmias from a recent pilot trial.
- Higher Dietary DHA/EPA Omega-3 Fatty Acids Associated with Lessened Progression in Age-related Vision Loss
Dr. J. P. SanGiovanni reported this afternoon, at the ISSFAL Congress in Cairns, Australia, on the relationship of dietary omega-3 intakes as DHA/EPA, found mainly in fish, to the deterioration in visual performance with aging.
- Higher Dietary DHA/EPA Omega-3 Fatty Acids Associated with Lessened Progression in Age-related Vision Loss
Dr. J. P. SanGiovanni reported this afternoon, at the ISSFAL Congress in Cairns, Australia, on the relationship of dietary omega-3 intakes as DHA/EPA, found mainly in fish, to the deterioration in visual performance with aging.
- Higher Dietary DHA/EPA Omega-3 Fatty Acids Associated with Lessened Progression in Age-related Vision Loss
Dr. J. P. SanGiovanni reported this afternoon, at the ISSFAL Congress in Cairns, Australia, on the relationship of dietary omega-3 intakes as DHA/EPA, found mainly in fish, to the deterioration in visual performance with aging.
- Higher Dietary DHA/EPA Omega-3 Fatty Acids Associated with Lessened Progression in Age-related Vision Loss
Dr. J. P. SanGiovanni reported this afternoon, at the ISSFAL Congress in Cairns, Australia, on the relationship of dietary omega-3 intakes as DHA/EPA, found mainly in fish, to the deterioration in visual performance with aging.
- Higher Dietary DHA/EPA Omega-3 Fatty Acids Associated with Lessened Progression in Age-related Vision Loss
Dr. J. P. SanGiovanni reported this afternoon, at the ISSFAL Congress in Cairns, Australia, on the relationship of dietary omega-3 intakes as DHA/EPA, found mainly in fish, to the deterioration in visual performance with aging.
- Higher Dietary DHA/EPA Omega-3 Fatty Acids Associated with Lessened Progression in Age-related Vision Loss
Dr. J. P. SanGiovanni reported this afternoon, at the ISSFAL Congress in Cairns, Australia, on the relationship of dietary omega-3 intakes as DHA/EPA, found mainly in fish, to the deterioration in visual performance with aging.
- Higher Dietary DHA/EPA Omega-3 Fatty Acids Associated with Lessened Progression in Age-related Vision Loss
Dr. J. P. SanGiovanni reported this afternoon, at the ISSFAL Congress in Cairns, Australia, on the relationship of dietary omega-3 intakes as DHA/EPA, found mainly in fish, to the deterioration in visual performance with aging.
- Higher Dietary DHA/EPA Omega-3 Fatty Acids Associated with Lessened Progression in Age-related Vision Loss
Dr. J. P. SanGiovanni reported this afternoon, at the ISSFAL Congress in Cairns, Australia, on the relationship of dietary omega-3 intakes as DHA/EPA, found mainly in fish, to the deterioration in visual performance with aging.
- Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award
The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology.
- Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award
The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology.
- Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award
The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- NPI Daily - Top of The News for Nov. 20, 2009 - FDA Issues 22 Warning Letters to Website Operators
Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award; Synergy Flavors Invests in Sensory Flavor Profiling Research; FDA Issues 22 Warning Letters to Website Operators; Nordic Naturals Ultimate Omega™ First Fish Oil to Participate in NFL/NFLPA Sports Nutrition Label Certification Program; BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates; New Organic Berry Whole Food Energy Bar from Amazing Grass Delivers Whole Food Nutrition; Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
- NPI Daily - Top of The News for Nov. 20, 2009 - FDA Issues 22 Warning Letters to Website Operators
Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award; Synergy Flavors Invests in Sensory Flavor Profiling Research; FDA Issues 22 Warning Letters to Website Operators; Nordic Naturals Ultimate Omega™ First Fish Oil to Participate in NFL/NFLPA Sports Nutrition Label Certification Program; BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates; New Organic Berry Whole Food Energy Bar from Amazing Grass Delivers Whole Food Nutrition; Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Spotlight on Savory Side Dishes
- Spotlight on Savory Side Dishes
- Spotlight on Savory Side Dishes
- Another Reason to Choose Healthy Lifestyle Habits
- Another Reason to Choose Healthy Lifestyle Habits
|
—Experts Fill in Gap to Promote Science-Based Regulation Internationally—
WASHINGTON, D.C., July 7, 2006 — The Council for Responsible Nutrition (CRN) has authored risk assessments for coenzyme Q10 (CoQ10), carotenoids lutein and lycopene, and creatine monohydrate. The risk assessments, published by the peer-reviewed journal Regulatory Toxicology and Pharmacology, were co-authored by CRN scientists John Hathcock, Ph.D., and Andrew Shao, Ph.D., to ensure regulators worldwide have a science-based guideline available to determine safe upper levels for these popular non-essential nutrients in dietary supplements.
"Coenzyme Q10, lutein, lycopene and creatine are becoming more popular and more prevalent in dietary supplements and a safe upper level has not as of yet been established by governing bodies for these nutrients," explains Dr. Shao, co-author of the risk assessment papers and vice president of scientific and regulatory affairs for CRN.
Applying a safety evaluation method he developed and which has been recognized internationally as a scientifically valid way to evaluate nutrient safety, CRN’s Dr. Hathcock, vice president of scientific and international affairs, along with his co-author Dr. Shao, reviewed clinical trials for the non-essential nutrients CoQ10, lutein, lycopene, and creatine to determine the safe upper level for supplements (ULS) for each. The values noted in the risk assessments are identified as the ULS, since dietary intakes from food sources were not taken into consideration.
The ULS values were derived using basic elements of the U.S. Food and Nutrition Board’s (FNB) methods as well as the observed safe limit (OSL) method, developed by Dr. Hathcock and now used as the highest observed intake (HOI) by the Food and Agriculture Organization and World Health Organization.
For each nutrient, Drs. Hathcock and Shao reviewed only randomized controlled trials (RCTs) conducted in humans, using uncontrolled trials and animal data as supportive information only. For CoQ10 the authors arrived at a ULS of 1,200 mg per day. For lutein the authors concluded that a ULS of 20 mg per day should be proposed for this carotenoid. For lycopene, the authors arrived at a ULS of 75 mg per day. Creatine was assigned a ULS of 5 grams per day.
Upper levels do not suggest that supplements taken above the level identified are unsafe, nor do they constitute a recommended intake. They simply identify a level at which there is "no known toxicity for these nutrients," said Dr. Hathcock. "Risk assessments allow us to put forth science-based guidelines for safety levels. Since there are no observed adverse effects for these nutrients, governing bodies haven’t set upper limits, leaving the door open for regulatory mischief. We’ve seen that happen before, especially in Europe where countries have tried setting limits a hundred times lower than observed safe levels, using, implicitly or overtly, the precautionary principle instead of science as justification. These risk assessments are necessary to ensure that science, not rhetoric, leads the way when it comes to safety."
The recently published risk assessments are currently available online through the International Society for Regulatory Toxicology and Pharmacology (ISRTP) and will be published in an upcoming issue of Regulatory Toxicology and Pharmacology, the official journal of ISRTP. Drs. Hathcock and Shao are also working on risk assessments for carnitine, and glucosamine and chondroitin sulfate, which have been accepted for upcoming publication in Regulatory Toxicology and Pharmacology.
Dr. Hathcock is also the author of the CRN publication, Vitamin and Mineral Safety, 2nd Edition, which provides an academic review of safety levels for 28 vitamins and minerals, with methodology, including CRN’s approach, on assessing safety along with a review of governmental and regulatory safety conclusions.
The Council for Responsible Nutrition (CRN), founded in 1973, is a Washington, D.C.-based trade association representing dietary supplement industry ingredient suppliers and manufacturers. CRN members adhere to a strong code of ethics, comply with dosage limits and manufacture dietary supplements to high quality standards under good manufacturing practices. |